Table 1.
Patient characteristics.
| Patients (n = 52) | |
|---|---|
| Age, years | |
| Median (range) | 59 (28–86) |
| Gender | |
| Male | 21 (40%) |
| Female | 31 (60%) |
| ECOG PS | |
| 0–1 | 45 (87%) |
| 2 | 5 (10%) |
| 3 | 2 (4%) |
| Histology | |
| Well or moderately differentiated | 33 (63%) |
| Poorly differentiated (Por), Signet-cell (Sig) or Mucinous (Muc) | 19 (37%) |
| MSI status | |
| MSI-High | 2 (4%) |
| Microsatellite stable | 10 (19%) |
| Unknown | 40 (77%) |
| Primary tumor site | |
| Right-sided | 30 (58%) |
| Left-sided | 22 (42%) |
| Site of metastasisa | |
| Liver | 30 (58%) |
| Lung | 19 (37%) |
| Peritoneum | 36 (69%) |
| Lymph node | 28 (54%) |
| Number of metastasis | |
| 1 | 10 (19%) |
| ⩾2 | 41 (81%) |
| Resection of primary tumor | |
| Yes | 37 (71%) |
| No | 15 (29%) |
| Adjuvant therapy | |
| Yes | 15 (29%) |
| No | 37 (71%) |
| WBC (/mm2 ) | |
| <10,000 | 43 (83%) |
| ⩾10,000 | 9 (17%) |
| LDH (IU/L) | |
| <240 | 28 (54%) |
| ⩾240 | 24 (46%) |
| ALP (IU/L) | |
| <300 | 17 (33%) |
| ⩾300 | 35 (67%) |
| Glasgow Prognostic Score | |
| 0 | 24 (48%) |
| 1 | 13 (26%) |
| 2 | 13 (26%) |
| Unknown | 2 (4%) |
| First-line chemotherapy | |
| Doublet with or without biologics | 43 (83%) |
| FOLFOXIRI with or without biologics | 15 (10%) |
| Others | 4 (8%) |
| PFS in first-line chemotherapy | |
| <6 months | 24 (46%) |
| ⩾6 months | 28 (54%) |
aThere is some overlap.
ALP, alkaline phosphatase; ECOG PS, Eastern Cooperative Oncology Group performance status; FOLFOXIRI, 5-FU/leucovorin+oxaliplatin+irinotecan; LDH, lactate dehydrogenase; MSI, microsatellite instability; PFS, progression-free survival; WBC, white blood cells.